Nacreon

RAPID IONS / THREE GOALS. ONE PLATFORM.

Delivery.
Safety.
Stability.

A peptide can do its job only if it gets where it needs to go, intact. Rapid Ions®, our ionic liquid technology, is built to help it get there.

Nacreon is developing a new delivery system for peptides: one that addresses biological barriers, starts with familiar ingredients, and protects the molecule during storage and shipping. The goal is more ways to deliver peptides without needles or a refrigerated supply chain.

THE FORMULATION

Change the environment.
Keep the peptide.

Rapid Ions® pairs citric acid with a common amino acid. Together, they form a charged system: one part negative, one part positive. This protic ionic liquid forms the excipient, the material that carries the active peptide.

The system is designed to create an ionic environment around the peptide without chemically modifying it. Think of a loose cloud of charge, rather than a sealed capsule.

That charge system also binds metal ions, including calcium and zinc. These ions help maintain biological barriers. Binding them locally gives us three angles on the delivery problem.

01 / DELIVERY

The scissors.
The net. The seam.

Three barriers stand between an oral peptide and the tissue beneath it. Rapid Ions® is designed to address all three.

The target is local, temporary action: protect the peptide, help it cross the barrier, and allow the barrier to recover.

ScissorsConceptual illustration: scissors represent peptide-cleaving enzymes; zinc is a target in some metal-dependent proteases. Not a molecular model or measured outcome. Zn

01 / ENZYMES

The scissors.

Proteases cut the bonds in peptides. Some depend on metal ions, including zinc, to work. Rapid Ions® is designed to bind those ions locally and reduce the activity of these metal-dependent enzymes.

NetConceptual illustration: an interwoven net represents mucus, with calcium at a connection. Local calcium binding is a design approach, not a demonstrated transport result. Ca

02 / MUCUS

The net.

Mucus is a sticky molecular network that can trap peptides at the surface. By binding calcium, the formulation aims to loosen that network and help the peptide move toward the tissue beneath it.

SeamConceptual illustration: adjoining cell shapes and a calcium-labeled connection represent the tight-junction barrier. Not a measured opening or recovery result. Ca

03 / TIGHT JUNCTIONS

The seam.

Tight junctions seal the spaces between epithelial cells. Calcium helps maintain those connections. Controlled, local binding aims to let peptides pass between cells, and barrier recovery is a central part of the research.

Conceptual illustrations of the design targets, not molecular models or measured outcomes.

LABORATORY SKIN MODEL

57×

Greater permeation than saline
in the tested skin model.

Measured in a skin model. A foundation to build on.

The first measured result comes from a different barrier: skin. In a 24-hour laboratory study using excised porcine skin, the Rapid Ions® formulation achieved 4.59% cumulative peptide permeation, compared with 0.08% for the saline control.

That result supports further delivery research. It does not establish oral absorption or human efficacy. Each peptide and delivery route needs its own evaluation.

PermeationLaboratory peptide permeation at 24 hours through excised porcine skin: Rapid Ions® 4.59 percent and saline control 0.08 percent. Bars share a zero-to-five-percent scale. This does not establish oral absorption or human efficacy.0%1%2%3%4%5% Rapid Ions® 4.59% Saline control 0.08%
Permeation MobileLaboratory peptide permeation at 24 hours through excised porcine skin: Rapid Ions® 4.59 percent and saline control 0.08 percent. Bars share a zero-to-five-percent scale. This does not establish oral absorption or human efficacy. Rapid Ions® 4.59% Saline control 0.08% 0% 2.5% 5%
Cumulative peptide permeation after 24 hours. Excised porcine skin; tested formulations only.

02 / SAFETY RESEARCH

Familiar ingredients.
A clear research priority.

Citric acid. A common amino acid. Familiar starting materials, with established uses in food and pharmaceutical formulations.

Familiar ingredients are a strong starting point. Proving the safety of the finished formulation, at its intended dose and delivery route, is the work ahead.

EARLY CELL RESPONSE

Encouraging laboratory results.

In CCK-8 testing at 24 and 48 hours, cell viability was 80–100%, with no statistically significant cytotoxicity reported.

The same studies found no acute immune activation and no inflammatory markers in the tested laboratory models. These early findings guide the next stage of safety research.

WHAT WE NEED TO PROVE

Safety in the intended use.

Our safety research needs to establish how tissues respond, how quickly barriers recover, and what happens with repeated exposure. Those questions depend on the peptide, concentration, formulation, and route.

Rapid Ions® has not yet been established as safe for human use. The purpose of this research is to build that evidence.

03 / STABILITY

Stability under
test conditions.

A delivery system also has to protect the peptide before it reaches the body.

Rapid Ions® creates a stabilizing formulation environment around the molecule. In our testing, peptides formulated with Rapid Ions® have remained stable at room temperature and after direct-sunlight exposure.

Room TemperatureA thermometer and storage container illustrate the room-temperature test condition.

ROOM TEMPERATURE

10 months

Stability observed in the tested Rapid Ions® peptide formulations.

SunlightA sun and storage container illustrate the direct-sunlight test condition.

DIRECT SUNLIGHT

10 days

No degradation observed in the tested Rapid Ions® peptide formulations.

Validated formulation
by formulation.

These results apply to the tested formulations. We establish storage conditions and shelf life formulation by formulation, against what each product needs.

THE DEVELOPMENT OPPORTUNITY

Beyond the needle.

Oral sprays. Tablets. Capsules. Buccal delivery through the cheek. Sublingual delivery under the tongue. These are the formats Nacreon is working to enable with Rapid Ions®.

Our R&D team leads the work, with third-party testing by university laboratories. The technical dossier is available on request, with the supporting data, methods, and results for the tested formulations.

Research-use formulations are not for human or veterinary use. Product development requires application-specific safety, efficacy, stability, and regulatory work.

START A TECHNICAL DISCUSSION

Bring us your peptide.

Tell us what you need to deliver, how you want to deliver it, and what stands in the way. We’ll share the relevant research and define an evaluation and licensing path.

Discuss Rapid Ions® ↗